vs
American Bitcoin Corp.（ABTC）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是American Bitcoin Corp.的1.1倍（$127.1M vs $118.0M），American Bitcoin Corp.同比增速更快（151.5% vs 17.1%），过去两年American Bitcoin Corp.的营收复合增速更高（296.9% vs 20.8%）
美国比特币公司专注于比特币相关业务领域。比特币是首个去中心化加密货币，由化名为中本聪的匿名人士于2008年发布白皮书后诞生，2009年随着开源代码上线正式投入使用，问世以来对全球金融与数字货币领域都产生了极为深远的影响。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
ABTC vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.1倍
$118.0M
营收增速更快
ABTC
高出134.4%
17.1%
两年增速更快
ABTC
近两年复合增速
20.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $118.0M | $127.1M |
| 净利润 | — | — |
| 毛利率 | 49.1% | 51.0% |
| 营业利润率 | -192.8% | -54.6% |
| 净利率 | — | — |
| 营收同比 | 151.5% | 17.1% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $-0.07 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABTCZLAB
| Q4 25 | $118.0M | $127.1M | ||
| Q3 25 | $64.2M | $115.4M | ||
| Q2 25 | $1.4M | $109.1M | ||
| Q1 25 | $1.6M | $105.7M | ||
| Q4 24 | $46.9M | $108.5M | ||
| Q3 24 | $11.6M | $101.8M | ||
| Q2 24 | $5.5M | $100.1M | ||
| Q1 24 | $7.5M | $87.1M |
净利润ABTCZLAB
| Q4 25 | — | — | ||
| Q3 25 | $3.5M | $-36.0M | ||
| Q2 25 | $3.4M | $-40.7M | ||
| Q1 25 | $-100.6M | $-48.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-576.0K | $-41.7M | ||
| Q2 24 | $-61.1M | $-80.3M | ||
| Q1 24 | $230.4M | $-53.5M |
毛利率ABTCZLAB
| Q4 25 | 49.1% | 51.0% | ||
| Q3 25 | 56.0% | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | 57.9% | 61.5% | ||
| Q3 24 | 4.2% | 64.1% | ||
| Q2 24 | 31.0% | 64.9% | ||
| Q1 24 | 35.4% | 61.4% |
营业利润率ABTCZLAB
| Q4 25 | -192.8% | -54.6% | ||
| Q3 25 | 11.2% | -42.3% | ||
| Q2 25 | -162.1% | -50.3% | ||
| Q1 25 | -350.8% | -53.3% | ||
| Q4 24 | — | -62.6% | ||
| Q3 24 | -87.8% | -66.6% | ||
| Q2 24 | -106.4% | -76.0% | ||
| Q1 24 | -20.8% | -80.7% |
净利率ABTCZLAB
| Q4 25 | — | — | ||
| Q3 25 | 5.4% | -31.2% | ||
| Q2 25 | 249.2% | -37.3% | ||
| Q1 25 | -6458.5% | -45.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -5.0% | -40.9% | ||
| Q2 24 | -1107.2% | -80.2% | ||
| Q1 24 | 3076.2% | -61.4% |
每股收益（稀释后）ABTCZLAB
| Q4 25 | $-0.07 | $-0.05 | ||
| Q3 25 | $0.06 | $-0.03 | ||
| Q2 25 | $-0.07 | $-0.04 | ||
| Q1 25 | $-0.09 | $-0.04 | ||
| Q4 24 | $1.10 | $-0.09 | ||
| Q3 24 | $-0.15 | $-0.04 | ||
| Q2 24 | $-0.10 | $-0.08 | ||
| Q1 24 | $-0.36 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $665.8M | $715.5M |
| 总资产 | $1.2B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABTCZLAB
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | $750.0K | $732.2M | ||
| Q1 25 | $367.0K | $757.3M | ||
| Q4 24 | $850.0K | $779.7M | ||
| Q3 24 | $478.0K | $616.1M | ||
| Q2 24 | $1.4M | $630.0M | ||
| Q1 24 | $1.9M | $650.8M |
股东权益ABTCZLAB
| Q4 25 | $665.8M | $715.5M | ||
| Q3 25 | $575.5M | $759.9M | ||
| Q2 25 | $339.7M | $791.7M | ||
| Q1 25 | $115.8M | $810.8M | ||
| Q4 24 | $1.0B | $840.9M | ||
| Q3 24 | $697.5M | $667.7M | ||
| Q2 24 | $614.3M | $704.2M | ||
| Q1 24 | $696.8M | $762.2M |
总资产ABTCZLAB
| Q4 25 | $1.2B | $1.2B | ||
| Q3 25 | $1.2B | $1.2B | ||
| Q2 25 | $6.2M | $1.2B | ||
| Q1 25 | $9.0M | $1.2B | ||
| Q4 24 | $1.1B | $1.2B | ||
| Q3 24 | $7.5M | $985.3M | ||
| Q2 24 | $11.4M | $987.4M | ||
| Q1 24 | $17.8M | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-79.6M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流ABTCZLAB
| Q4 25 | $-79.6M | $-26.0M | ||
| Q3 25 | $-39.0M | $-32.0M | ||
| Q2 25 | $-879.0K | $-31.0M | ||
| Q1 25 | $-3.2M | $-61.7M | ||
| Q4 24 | $-54.0M | $-55.8M | ||
| Q3 24 | $-76.8M | $-26.8M | ||
| Q2 24 | $201.0K | $-42.2M | ||
| Q1 24 | $-983.0K | $-90.1M |
自由现金流ABTCZLAB
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | $-1.4M | $-33.9M | ||
| Q1 25 | — | $-63.2M | ||
| Q4 24 | $-60.6M | $-58.4M | ||
| Q3 24 | $-79.3M | $-28.2M | ||
| Q2 24 | $-874.0K | $-42.9M | ||
| Q1 24 | — | $-91.1M |
自由现金流率ABTCZLAB
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | -104.4% | -31.1% | ||
| Q1 25 | — | -59.9% | ||
| Q4 24 | -129.2% | -53.8% | ||
| Q3 24 | -683.2% | -27.7% | ||
| Q2 24 | -15.8% | -42.9% | ||
| Q1 24 | — | -104.5% |
资本支出强度ABTCZLAB
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | 40.5% | 2.6% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | 14.1% | 2.4% | ||
| Q3 24 | 21.6% | 1.3% | ||
| Q2 24 | 19.5% | 0.7% | ||
| Q1 24 | — | 1.1% |
现金转化率ABTCZLAB
| Q4 25 | — | — | ||
| Q3 25 | -11.21× | — | ||
| Q2 25 | -0.26× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ABTC
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
